Medroxyprogesterone acetate (Synonyms: Medroxyprogesterone 17-acetate; Farlutin)

Name: Medroxyprogesterone acetate
Brand: MedChemExpress
SKU: HY-B0469
Rating: 5.0 (34 reviews)

Cat. No.: HY-B0469 Purity: 99.88%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors.

For research use only. We do not sell to patients.

CAS No. : 71-58-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 34 publication(s) in Google Scholar

Other Forms of Medroxyprogesterone acetate:

Medroxyprogesterone acetate-d₃ In-stock
Medroxyprogesterone acetate (Standard) In-stock
Medroxyprogesterone acetate-d₇ Get quote

34 Publications Citing Use of MCE Medroxyprogesterone acetate

In Vivo Efficacy Study

Apoptosis Analysis

Cell Proliferation/Viability Assay

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Nov;43(21):5018-5036. [Abstract]; Human ESC cell line (hESCs) was treated with 8-bromo-cAMP (0.5 mM) plus Medroxyprogesterone acetate (MPA, 1 μM) for different times, and westernblotting assay was used to detect the expression of CDKN2A, CDKN1A, TP53 (indicator of cell senescence) and PRL.

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: Mol Med. 2024 Sep 12;30(1):147. [Abstract]; The growth of subcutaneously transplanted tumors in mice (n=6). Daily intraperitoneal injections (100 mg/kg MA, Medroxyprogesterone acetate) were administered, and tumor size was measured every 4 days to calculate tumor volume.

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: Mol Med. 2024 Sep 12;30(1):147. [Abstract]; TUNEL staining to detect apoptosis of tumor cells in mice in each group (n=6), daily intraperitoneal injections (100 mg/kg MA, Medroxyprogesterone acetate) were administered.

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]; Cisplatin-resistant OVCAR-1 CP were pretreated with three indicated drugs (Farlutin, 10 μM) for 24 h before treatment with cisplatin for another 6 h (Scale bar: 5 μm). The localization of NPM1 was detected by immunofluorescence to indicate the ribosomal stress.

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]; The cells were pretreated with the three indicated drugs for 24 h (Farlutin, 10 μM). Colony-formation assay was used to determine the drug sensitivity to cisplatin.

: Medroxyprogesterone acetate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]; Cell viability assay was performed for cisplatin treated ovarian cancer organoids with/without pretreatment with Farlutin, 10 μM, 120 h.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Purity & Documentation
References
Customer Review

Description

Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors^[1].

IC₅₀ & Target

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	EC₅₀	10 nM Compound: 2 (MPA)	Effective concentration against glucocorticoid receptor in human lung A549 cells Effective concentration against glucocorticoid receptor in human lung A549 cells	[PMID: 12657272]
AN3-CA	IC₅₀	37.1 μM Compound: MPA	Antiproliferative activity against human AN3CA cells assessed as inhibition of cell viability by CCK8 assay Antiproliferative activity against human AN3CA cells assessed as inhibition of cell viability by CCK8 assay	[PMID: 32527541]
CV-1	EC₅₀	0.15 nM Compound: 3 (MPA)	Agonistic activity against human progesterone receptor expressed in CV-1 cells Agonistic activity against human progesterone receptor expressed in CV-1 cells	[PMID: 12954062]
CV-1	EC₅₀	0.15 nM Compound: MPA	Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells Compound was tested for agonistic activity by cotransfection assay against human Progesterone receptor in CV-1 cells	[PMID: 10212133]
CV-1	EC₅₀	0.15 nM Compound: MPA	Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay. Agonistic activity to the human progesterone receptor (hPR)assayed in CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	EC₅₀	0.15 nM Compound: MPA	Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells. Agonistic activity was measured for modulation of hPR-B (human progesterone receptor) in co-transfected CV-1 cells.	[PMID: 9464361]
CV-1	EC₅₀	0.15 nM Compound: MPA	Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell Effective concentration (EC50) against human progesterone receptor expressed in CV-1 cell	[PMID: 9784110]
CV-1	EC₅₀	10 nM Compound: MPA	Agonist activity against Human glucocorticoid receptor(hGR) expressed in CV-1 cells Agonist activity against Human glucocorticoid receptor(hGR) expressed in CV-1 cells	[PMID: 9464360]
CV-1	EC₅₀	6.1 nM Compound: MPA	Agonistic activity against Human androgen receptor(hAR) expressed in CV-1 cells Agonistic activity against Human androgen receptor(hAR) expressed in CV-1 cells	[PMID: 9464360]
CV-1	EC₅₀	924 nM Compound: MPA	Agonistic activity against Human estrogen receptor(hER) expressed in CV-1 cells Agonistic activity against Human estrogen receptor(hER) expressed in CV-1 cells	[PMID: 9464360]
CV-1	IC₅₀	10 nM Compound: MPA	Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human glucocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	1197 nM Compound: MPA	Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human mineralocorticoid receptor(hMR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
CV-1	IC₅₀	1197 nM Compound: MPA	Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells Inhibitory activity (IC50) against human mineralocorticoid receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	6.1 nM Compound: MPA	Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	924 nM Compound: MPA	IC50 determined against human estrogen receptor in CV-1 cells IC50 determined against human estrogen receptor in CV-1 cells	[PMID: 9784110]
CV-1	IC₅₀	< 10000 nM Compound: MPA	Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay. Antagonistic activity was determined in Human progesterone receptor(hPR) of CV-1 cells in cotransfection assay.	[PMID: 9464360]
HEC-1-A	IC₅₀	51.8 μM Compound: MPA	Antiproliferative activity against human Hec1A cells assessed as inhibition of cell viability by CCK8 assay Antiproliferative activity against human Hec1A cells assessed as inhibition of cell viability by CCK8 assay	[PMID: 32527541]
Ishikawa	IC₅₀	37 μM Compound: MPA	Antiproliferative activity against human Ishikawa cells assessed as inhibition of cell viability by CCK8 assay Antiproliferative activity against human Ishikawa cells assessed as inhibition of cell viability by CCK8 assay	[PMID: 32527541]
KLE	IC₅₀	> 80 μM Compound: MPA	Antiproliferative activity against human KLE cells assessed as inhibition of cell viability by CCK8 assay Antiproliferative activity against human KLE cells assessed as inhibition of cell viability by CCK8 assay	[PMID: 32527541]
L929	EC₅₀	6.1 nM Compound: 2 (MPA)	Effective concentration against Androgen receptor in mouse fibroblast L929 cells Effective concentration against Androgen receptor in mouse fibroblast L929 cells	[PMID: 12657272]
T47D	EC₅₀	0.1 nM Compound: MPA (Medroxyprogesterone)	Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line. Effective concentration on alkaline phosphatase activity in human T47D breast carcinoma cell line.	[PMID: 12657271]
T47D	EC₅₀	0.12 nM Compound: MPA	Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line Agonistic activity against progesterone receptor in alkaline phosphatase assay using human T47D breast carcinoma cell line	[PMID: 11859003]
T47D	EC₅₀	0.33 nM Compound: 3 (MPA)	Agonistic activity against human progesterone receptor in T47D breast cancer cells Agonistic activity against human progesterone receptor in T47D breast cancer cells	[PMID: 12954062]
T47D	EC₅₀	0.33 nM Compound: MPA	Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells Agonistic activity by cotransfection assay against human Progesterone receptor in T47D cells	[PMID: 10212133]
T47D	EC₅₀	0.4 nM Compound: MPA	Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity Agonist activity at human progesterone receptor in human T47D cells assessed as alkaline phosphatase activity	[PMID: 18553958]
T47D	EC₅₀	0.5 nM Compound: 2 (MPA)	Effective concentration of progesterone receptor agonist induction of alkaline phosphatase activity in human T47D breast carcinoma cells Effective concentration of progesterone receptor agonist induction of alkaline phosphatase activity in human T47D breast carcinoma cells	[PMID: 12657272]
T47D	EC₅₀	0.5 nM Compound: MPA	Agonistic activity measures the ability to induce alkaline phosphatase in T47D human breast cancer cell line Agonistic activity measures the ability to induce alkaline phosphatase in T47D human breast cancer cell line	[PMID: 15081005]
T47D	IC₅₀	10.8 nM Compound: 2 (MPA)	Inhibition of 3 nM [3H]R5020 binding to progesterone receptor in human T47D cells Inhibition of 3 nM [3H]R5020 binding to progesterone receptor in human T47D cells	[PMID: 12657272]
T47D	IC₅₀	10.8 nM Compound: MPA	Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells Binding affinity for Progesterone receptor (PR) in human T47D breast carcinoma cells	[PMID: 11859003]
T47D	IC₅₀	10.8 nM Compound: MPA (Medroxyprogesterone)	Inhibition of [3H]P4 to progesterone receptor (PR) of human T47D breast carcinoma cells Inhibition of [3H]P4 to progesterone receptor (PR) of human T47D breast carcinoma cells	[PMID: 12657271]

In Vitro

Medroxyprogesterone acetate (10 and 0.5 nM, 48 h) inhibits Steroid-deprived HUVEC eNOS expression^[2].
Medroxyprogesterone acetate (10 and 0.5 nM, 16 h) inhibits leukocyte adhesion to human endothelial cells (Steroid-deprived HUVECs) by reduing endothelial adhesion molecule (VCAM-1 and ICAM-1 protein) expression^[2].
Medroxyprogesterone acetate (10 and 0.5 nM, 2 h) reduces NF-κB nuclear translocation in Steroid-deprived HUVECs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[2]

Cell Line:	100 ng/ml LPS treated endothelial cells
Concentration:	10 and 0.5 nM
Incubation Time:	2h
Result:	Inhibited NF-κB nuclear translocation.

In Vivo

Medroxyprogesterone acetate (5 mg/kg, oral gavage, rats) shows a C_max of 377.9 ng/mL, AUC_0- 2535.9 ng·h/mL, t_1/2 of 10.2 h^[3].
Medroxyprogesterone acetate (0.05-0.2 mg/kg/day, p.o., 14 days, rats) increases allopregnanolone levels in all tissues except in the adrenal gland, and affects β-END levels in the hippocampus^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

386.52

Formula

C₂₄H₃₄O₄

CAS No.

71-58-9

Appearance

Solid

Color

White to off-white

SMILES

CC(O[C@@]([C@]12C)(CC[C@@]1([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC2)C(C)=O)=O

Structure Classification

Steroids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (25.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 6.25 mg/mL (16.17 mM; ultrasonic and warming and heat to 60°C)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5872 mL	12.9359 mL	25.8719 mL
5 mM	0.5174 mL	2.5872 mL	5.1744 mL
10 mM	0.2587 mL	1.2936 mL	2.5872 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 1 mg/mL (2.59 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 25 mg/mL (64.68 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.88%

Select Batch:

Data Sheet (280 KB) SDS (418 KB)

COA (252 KB) LCMS (266 KB)

Handling Instructions (2659 KB)

References

[1]. Schindler AE, et al. Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. [Content Brief]

[2]. Simoncini T, et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology. 2004 Dec;145(12):5745-56. [Content Brief]

[3]. Smith D, et al. Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Biopharm Drug Dispos. 1993 May;14(4):341-55. [Content Brief]

[4]. Bernardi F, et al. Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. Neuroendocrinology. 2006;83(5-6):348-59. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.5872 mL	12.9359 mL	25.8719 mL	64.6797 mL
	5 mM	0.5174 mL	2.5872 mL	5.1744 mL	12.9359 mL
	10 mM	0.2587 mL	1.2936 mL	2.5872 mL	6.4680 mL
	15 mM	0.1725 mL	0.8624 mL	1.7248 mL	4.3120 mL
DMSO	20 mM	0.1294 mL	0.6468 mL	1.2936 mL	3.2340 mL
DMSO	25 mM	0.1035 mL	0.5174 mL	1.0349 mL	2.5872 mL

Medroxyprogesterone acetate Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Medroxyprogesterone71-58-9Medroxyprogesterone 17-acetate FarlutinProgesterone ReceptorAndrogen ReceptorGlucocorticoid ReceptorEndogenous MetaboliteNR3C3Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Medroxyprogesterone acetate (Synonyms: Medroxyprogesterone 17-acetate; Farlutin)

Customer Review

Other Forms of Medroxyprogesterone acetate:

Medroxyprogesterone acetate Related Antibodies

34 Publications Citing Use of MCE Medroxyprogesterone acetate

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Medroxyprogesterone acetate Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Medroxyprogesterone acetate Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report